Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22515570 | 0.83 | NOTUM (0.38) | NOTUMPIK3CG | |
| SCHEMBL8738333 | 0.80 | PIK3CG (0.36) | PIK3CGNPC1HTTRAB9ASMN1; SMN2 | |
| SCHEMBL15945546 | 0.80 | NPC1 (0.45) | PIK3CGNPC1HTTRAB9ASMN1; SMN2 | |
| SCHEMBL21709605 | 0.78 | PIK3CG (0.39) | NOTUMPIK3CGAOC3NPC1HTT | |
| SCHEMBL506677 | 0.78 | PIK3CG (0.35) | PIK3CGNPC1HTTRAB9ASMN1; SMN2 | |
| SCHEMBL10228806 | 0.78 | PIK3CG (0.35) | PIK3CGNPC1HTTRAB9ASMN1; SMN2 | |
| SCHEMBL24259026 | 0.77 | SIRT2 (0.39) | PIK3CGNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18997069 | 0.77 | PIK3CG (0.34) | PIK3CGNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16544514 | 0.77 | SMN1; SMN2 (0.41) | PIK3CGNPC1HTTRAB9ASMN1; SMN2 | |
| SCHEMBL1785672 | 0.75 | PIK3CG (0.37) | PIK3CGAOC3NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200048288-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-13 | — | — | US | disclosed |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | NOTUM 3121/4885PIK3CG 55/4885AOC3 4818/4885 |
| US-20200048288-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | NOTUM 3121/4885PIK3CG 55/4885AOC3 4818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.